Abstract
Prophylactic cranial irradiation (PCI) has been considered standard of care for patients with limited-stage small-cell lung cancer who achieve complete response to definitive treatment after a meta-analysis revealed its favorable effects on survival. In a European trial, PCI was also shown to confer a survival advantage for patients with extensive-stage (ES) SCLC who experienced any positive response after initial chemotherapy, leading to PCI also being considered a standard treatment for these patients as well. However, a recent Japanese trial investigating PCI for patients with ES-SCLC was stopped early when an interim analysis failed to confirm a survival benefit. This finding has motivated the thoracic oncology community to rethink the role of PCI in ES-SCLC.
Original language | English (US) |
---|---|
Pages (from-to) | 339-343 |
Number of pages | 5 |
Journal | Radiotherapy and Oncology |
Volume | 127 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2018 |
Keywords
- Brain imaging
- Neurocognitive function
- Prophylactic cranial irradiation
- Quality of life
- Small cell lung cancer
ASJC Scopus subject areas
- Hematology
- Oncology
- Radiology Nuclear Medicine and imaging